Pennant Group Valuation

Is 1ZU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1ZU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1ZU (€31.2) is trading below our estimate of fair value (€38.85)

Significantly Below Fair Value: 1ZU is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1ZU?

Other financial metrics that can be useful for relative valuation.

1ZU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA40.9x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does 1ZU's PE Ratio compare to its peers?

The above table shows the PE ratio for 1ZU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.1x
SYAB SYNLAB
28.3xn/a€2.5b
FME Fresenius Medical Care
19.6x21.3%€10.4b
FRE Fresenius SE KGaA
26x24.1%€18.7b
RHK RHÖN-KLINIKUM
18.6x5.1%€863.5m
1ZU Pennant Group
59.1x26.6%€1.2b

Price-To-Earnings vs Peers: 1ZU is expensive based on its Price-To-Earnings Ratio (59.1x) compared to the peer average (23.1x).


Price to Earnings Ratio vs Industry

How does 1ZU's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 1ZU is expensive based on its Price-To-Earnings Ratio (59.1x) compared to the European Healthcare industry average (18.5x).


Price to Earnings Ratio vs Fair Ratio

What is 1ZU's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1ZU PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio59.1x
Fair PE Ratio28.1x

Price-To-Earnings vs Fair Ratio: 1ZU is expensive based on its Price-To-Earnings Ratio (59.1x) compared to the estimated Fair Price-To-Earnings Ratio (28.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1ZU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€30.20
€34.77
+15.1%
5.8%€37.08€31.52n/a4
Oct ’25€29.80
€30.10
+1.0%
14.9%€35.94€23.36n/a4
Sep ’25€30.40
€28.60
-5.9%
10.4%€30.87€23.60n/a4
Aug ’25€28.00
€25.24
-9.9%
3.1%€25.70€23.86n/a4
Jul ’25€21.20
€23.43
+10.5%
2.0%€23.89€22.98n/a4
Jun ’25€21.60
€23.43
+8.5%
2.0%€23.89€22.98n/a4
May ’25€19.30
€20.70
+7.3%
3.2%€21.65€19.76n/a4
Apr ’25€18.50
€19.68
+6.4%
2.3%€20.14€19.22n/a4
Mar ’25€17.40
€17.99
+3.4%
16.4%€20.30€12.92n/a4
Feb ’25€14.20
€14.62
+3.0%
8.8%€16.45€12.80n/a4
Jan ’25€12.70
€13.54
+6.6%
6.0%€14.94€13.07n/a4
Dec ’24€12.40
€13.54
+9.2%
6.0%€14.94€13.07n/a4
Nov ’24€10.20
€12.98
+27.2%
7.6%€14.57€11.84€30.204
Oct ’24€10.70
€12.98
+21.3%
7.6%€14.57€11.84€29.804
Sep ’24€10.90
€12.98
+19.1%
7.6%€14.57€11.84€30.404
Aug ’24€10.40
€13.17
+26.6%
6.4%€14.37€12.57€28.003
Jul ’24€11.40
€14.22
+24.8%
6.1%€14.84€12.99€21.203
Jun ’24€11.20
€14.26
+27.3%
6.1%€14.88€13.02€21.603
May ’24€12.30
€15.18
+23.4%
7.8%€16.31€13.59€19.304
Apr ’24€13.20
€15.65
+18.6%
7.2%€16.97€14.14€18.505
Mar ’24€13.90
€15.65
+12.6%
7.2%€16.97€14.14€17.405
Feb ’24€11.90
€14.81
+24.4%
15.1%€17.31€11.54€14.205
Jan ’24€10.10
€14.81
+46.6%
15.1%€17.31€11.54€12.705
Dec ’23€10.20
€14.81
+45.2%
15.1%€17.31€11.54€12.405
Nov ’23€13.10
€18.41
+40.5%
22.5%€23.52€12.27€10.205

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies